P2P review · GLP-1 receptor agonist
Semaglutide (Wegovy/Ozempic) P2P review prep
GLP-1 receptor agonist. Indications: Type 2 diabetes (Ozempic), obesity (Wegovy)
Drug class
GLP-1 receptor agonist
Payer criteria typically applied
- Step therapy with metformin failed
- T2DM with A1c >7
- Obesity dx with BMI ≥30 or ≥27 with comorbidity
Common medical director objections
- Insufficient T2DM control on metformin
- Wegovy: 6-month lifestyle attempt
- Concurrent insulin not required
Pitfalls to avoid
- Ozempic for obesity-only — typically denied (use Wegovy)
- Wegovy without 6-month lifestyle attempt
- PCOS-only indication
Frequently asked questions
What does the payer typically require for Semaglutide (Wegovy/Ozempic)?
Step therapy with metformin failed; T2DM with A1c >7; Obesity dx with BMI ≥30 or ≥27 with comorbidity.
What objections does the medical director typically raise?
Insufficient T2DM control on metformin; Wegovy: 6-month lifestyle attempt; Concurrent insulin not required.
What pitfalls should I avoid during the P2P call?
Ozempic for obesity-only — typically denied (use Wegovy); Wegovy without 6-month lifestyle attempt; PCOS-only indication.
Related class drugs
Sources
Prep Semaglutide (Wegovy/Ozempic) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com